Assertio Holdings, INC 8-K filings

Assertio Holdings has completed its acquisition by Zydus Worldwide DMCC in an all-cash transaction valued at $23.50 per share.

Assertio Holdings, Inc. announced a definitive agreement to be acquired by Zydus Worldwide DMCC through a cash tender offer of $23.50 per share.

Assertio Holdings, Inc. announced a definitive agreement with Zydus Worldwide DMCC to be acquired for $23.50 per share in an all-cash tender offer, totaling approximately $166.4 million.

Assertio Holdings and Garda Therapeutics have mutually agreed to postpone the tender offer for Assertio's shares and convertible notes to May 14, 2026.

Assertio Holdings stockholders approved an increase in shares for the 2014 Omnibus Incentive Plan and elected six directors at the 2026 Annual Meeting.

Assertio Holdings and Garda Therapeutics mutually agree to postpone the tender offer commencement to May 8, 2026, impacting the acquisition timeline.

Assertio Holdings, Inc. has entered into an Amended and Restated Agreement and Plan of Merger with Garda Therapeutics, Inc., increasing the all-cash tender offer price to $21.80 per share.

Assertio Holdings and Garda Therapeutics have mutually agreed to extend the tender offer deadline for Assertio's acquisition to May 4, 2026.

Assertio Holdings announced that Garda Therapeutics will commence a tender offer to acquire all outstanding shares for $18.00 per share on April 29, 2026.

Assertio Holdings, Inc. has completed the sale of several product franchises to Cosette Pharmaceuticals, Inc. for $35 million upfront, with potential for additional milestone payments.

Assertio Holdings, Inc. announced a definitive agreement to be acquired by Garda Therapeutics for $18 per share in cash, plus a contingent value right, and simultaneously divested its non-Rolvedon assets to Cosette Pharmaceuticals.

Assertio Holdings, Inc. reported fourth quarter and full year 2025 financial results, surpassing its full-year guidance for net product sales and Adjusted EBITDA, while providing a positive outlook for 2026.

Assertio Holdings, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the matter.

Assertio Holdings, Inc. will implement a 1-for-15 reverse stock split of its common stock, effective December 26, 2025, following stockholder approval.

Assertio Holdings announced that former CEO Brendan P. O'Grady resigned from its Board of Directors following the execution of a waiver and release agreement.

Assertio Holdings reports strong third-quarter 2025 financial results driven by Rolvedon sales, narrows full-year guidance, and promotes Paul Schwichtenberg to President and COO.

Assertio Holdings, Inc. announced the immediate departure of CEO Brendan O'Grady and the appointment of board member Mark Reisenauer as his successor.

Assertio Holdings' subsidiary, Spectrum Pharmaceuticals, amended its supply agreement for ROLVEDON drug substance, securing a mid-single digit price reduction and long-term pricing.

Assertio Holdings reports a significant GAAP net loss in Q2 2025 but shows improved Adjusted EBITDA and cash position, narrowing full-year guidance amidst strategic transformation.

Assertio Holdings' stockholders approved an amendment to the 2014 Omnibus Incentive Plan, increasing the number of shares available for issuance, and authorized a reverse stock split at the Annual Meeting on May 7, 2025.

Assertio Holdings reports first quarter 2025 financial results with net product sales of $26.0 million, aligning with its 2025 outlook, and provides an update on its long-term business strategy.

Assertio Holdings reports Q4 net product sales of $29.6 million and full-year sales of $120.8 million, with a strategic focus on Rolvedon and potential acquisitions for future growth.

Assertio Holdings, Inc. received a notification from Nasdaq regarding potential delisting due to its common stock price falling below the required $1.00 per share for an extended period.

Assertio Holdings has appointed a new Chief Transformation Officer, Chief Commercial Officer, and a new member to its Board of Directors.

Assertio Holdings reported its third quarter 2024 financial results, highlighted by stable Rolvedon sales and strategic board changes, while addressing recent market challenges.

Assertio Holdings announced its second quarter 2024 financial results, highlighting growth in Rolvedon sales but a decrease in Indocin sales due to generic competition.

Assertio Holdings' annual meeting saw stockholders approve an increase in shares for the 2014 Omnibus Incentive Plan and the board approve a bylaw amendment clarifying special meeting requirements.

Assertio Holdings has appointed Brendan P. O'Grady as its new Chief Executive Officer, effective May 29, 2024, replacing interim CEO Heather L. Mason.

Assertio Holdings reported a mixed first quarter of 2024, with strong growth in Rolvedon sales offset by a decline in Indocin sales due to generic competition.

James L. Tyree, Chairman of the Compensation Committee of Assertio Holdings, has declined to stand for re-election due to disagreements over board retirement policies.